RecruitingNot applicableNCT06478472

Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

Studying MALT lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The First Affiliated Hospital of Xiamen University
Principal Investigator
Bing Xu, MD, PhD
The First Aiffiliated hosptical of xiamen University
Intervention
Orelabrutinib in combination with rituximab(drug)
Enrollment
36 enrolled
Eligibility
18 years · All sexes
Timeline
2024 – 2027

Study locations (1)

Collaborators

The First Hospital of Jilin University · Fujian Cancer Hospital · Guangdong Provincial People's Hospital · Nanfang Hospital, Southern Medical University · The Second Affiliated Hospital of Dalian Medical University · Jiangxi Provincial Cancer Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Shanxi Province Cancer Hospital · Chinese PLA General Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06478472 on ClinicalTrials.gov

Other trials for MALT lymphoma

Additional recruiting or active studies for the same condition.

See all trials for MALT lymphoma →

← Back to all trials